EGFR inhibitors, MHC expression and immune responses: Can EGFR inhibitors be used as immune response modifiers?

OncoImmunology

Volumn 1, Issue 1, 2012, Pages 71-74

  Pollack, Brian P ^a,b,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Egfr; Egfr inhibitor; Immune response modifier; Immunotherapy; Mhc

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN EXPRESSION; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; COMPLEX FORMATION; CYTOKINE RESPONSE; DRUG MECHANISM; GENE EXPRESSION REGULATION; HUMAN; IMMUNE RESPONSE; IMMUNE RESPONSE GENE; IMMUNOREGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; SIGNAL TRANSDUCTION; SKIN CANCER;

EID: 84886944522     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.1.1.18073     Document Type: Short Survey

References (30)

1. Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology 2009; 77:400-10; PMID:20130423; DOI:10.1159/000279388.
2. Gusterson BA, Hunter KD. Should we be surprised at the paucity of response to EGFR inhibitors? Lancet Oncol 2009; 10:522-7; PMID:19410197; DOI:10.1016/S1470-2045(09)70034-8.
3. Arbiser JL. Why targeted therapy hasn't worked in advanced cancer. J Clin Invest 2007; 117:2762-5; PMID:17909624; DOI:10.1172/JCI33190.
4. Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23:5235-46; PMID:16051966; DOI:10.1200/JCO.2005.00.6916.
5. Pollack BP, Sapkota B, Cartee TV. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin Cancer Res 2011; 17:4400-13; PMID:21586626; DOI:10.1158/1078-0432.CCR-10-3283.
6. Garrido F, Cabrera T, Aptsiauri N. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 2010; 127:249-56; PMID:20178101.
7. Lotem M, Machlenkin A, Hamburger T, Nissan A, Kadouri L, Frankenburg S, et al. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells. Clin Cancer Res 2009; 15:4968-77; PMID:19602547; DOI:10.1158/1078-0432.CCR-08-3320.
8. Mortara L, Castellani P, Meazza R, Tosi G, De Lerma Barbaro A, Procopio FA, et al. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection and specific antitumor memory. Clin Cancer Res 2006; 12:3435-43; PMID:16740768; DOI:10.1158/1078-0432.CCR-06-0165.
9. Lampen MH, van Hall T. Strategies to counteract MHC-I defects in tumors. Curr Opin Immunol 2011; 23:293-8; PMID:21295956; DOI:10.1016/j.coi.2010.12.005.
10. Burova E, Vassilenko K, Dorosh V, Gonchar I, Nikolsky N. Interferon gamma-dependent transactivation of epidermal growth factor receptor. FEBS Lett 2007; 581:1475-80; PMID:17362940; DOI:10.1016/j.febslet.2007.03.002.
11. Mitra RS, Nickoloff BJ. Epidermal growth factor and transforming growth factor-alpha decrease gamma interferon receptors and induction of intercellular adhesion molecule (ICAM-1) on cultured keratinocytes. J Cell Physiol 1992; 150:264-8; PMID:1346399; DOI:10.1002/jcp.1041500207.
12. Boss JM, Jensen PE. Transcriptional regulation of the MHC class II antigen presentation pathway. Curr Opin Immunol 2003; 15:105-11; PMID:12495741; DOI:10.1016/S0952-7915(02)00015-8.
13. Martin BK, Chin KC, Olsen JC, Skinner CA, Dey A, Ozato K, et al. Induction of MHC class I expression by the MHC class II transactivator CIITA. Immunity 1997; 6:591-600; PMID:9175837; DOI:10.1016/S1074-7613(00)80347-7.
14. González PA, Carreno LJ, Coombs D, Mora JE, Palmieri E, Goldstein B, et al. T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell. Proc Natl Acad Sci USA 2005; 102:4824-9; PMID:15772168; DOI:10.1073/pnas.0500922102.
15. Leignadier J, Labrecque N. Epitope density influences CD8+ memory T cell differentiation. PLoS ONE 2010; 5:13740; PMID:21060788; DOI:10.1371/journal.pone.0013740.
16. Corse E, Gottschalk RA, Allison JP. Strength of TCR-peptide/MHC interactions and in vivo T cell responses. J Immunol 2011; 186:5039-45; PMID:21505216; DOI:10.4049/jimmunol.1003650.
17. Gerber PA, Enderlein E, Homey B. The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects. J Clin Oncol 2008; 26:2790-2; PMID:18509193; DOI:10.1200/JCO.2007.16.0077.
18. Zorzou MP, Stratigos A, Efstathiou E, Bamias A. Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor. Acta Derm Venereol 2004; 84:308-9; PMID:15339078; DOI:10.1080/00015550410024634.
19. Hermanns JF, Pierard GE, Quatresooz P. Erlotinib-responsive actinic keratoses. Oncol Rep 2007; 18:581-4.
20. Mascia F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003; 163:303-12; PMID:12819035; DOI:10.1016/S0002-9440(10)63654-1.
21. Yao Y, Wolverton JE, Zhang Q, Marathe GK, Al-Hassani M, Konger RL, et al. Ultraviolet B radiation generated platelet-activating factor receptor agonist formation involves EGF-R-mediated reactive oxygen species. J Immunol 2009; 182:2842-8; PMID:19234179; DOI:10.4049/jimmunol.0802689.
22. Schwarz T. Photoimmunosuppression. Photodermatol Photoimmunol Photomed 2002; 18:141-5; PMID:12207678; DOI:10.1034/j.1600-0781.2002.180307.x.
23. El-Abaseri TB, Fuhrman J, Trempus C, Shendrik I, Tennant RW, Hansen LA. Chemoprevention of UV light-induced skin tumorigenesis by inhibition of the epidermal growth factor receptor. Cancer Res 2005; 65:3958-65; PMID:15867397; DOI:10.1158/0008-5472.CAN-04-2204.
24. Pivarcsi A, Muller A, Hippe A, Rieker J, van Lierop A, Steinhoff M, et al. Tumor immune escape by the loss of homeostatic chemokine expression. Proc Natl Acad Sci USA 2007; 104:19055-60; PMID:18025475; DOI:10.1073/pnas.0705673104.
25. Zaidi MR, Davis S, Noonan FP, Graff-Cherry C, Hawley TS, Walker RL, et al. Interferon-gamma links ultraviolet radiation to melanomagenesis in mice. Nature 2011; 469:548-53; PMID:21248750; DOI:10.1038/nature09666.
26. Ryan MA, Nattamai KJ, Xing E, Schleimer D, Daria D, Sengupta A, et al. Pharmacological inhibition of EGFR signaling enhances G-CSF-induced hematopoietic stem cell mobilization. Nat Med 2010; 16:1141-6; PMID:20871610; DOI:10.1038/nm.2217.
27. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011; 17:589-95; PMID:21516087; DOI:10.1038/nm.2341.
28. Yang H, Kim SK, Kim M, Reche PA, Morehead TJ, Damon IK, et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest 2005; 115:379-87.
29. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364:2119-27; PMID:21631324; DOI:10.1056/NEJMoa1012863.
30. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; DOI:10.1056/NEJMoa1003466.